Switch to:
Progenics Pharmaceuticals Inc (NAS:PGNX)
EV/EBIT
-13.24 (As of Today)

EV/EBIT ratio is calculated as enterprise value divided by its Earnings Before Interest and Taxes (EBIT). As of today, Progenics Pharmaceuticals Inc's enterprise value is $520.45 Mil. Progenics Pharmaceuticals Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2016 was $-39.30 Mil. Therefore, Progenics Pharmaceuticals Inc's EV/EBIT ratio for today is -13.24.

PGNX' s EV/EBIT Range Over the Past 10 Years
Min: -50.8   Max: 301.4
Current: 49.71

-50.8
301.4

During the past 13 years, the highest EV/EBIT Ratio of Progenics Pharmaceuticals Inc was 301.40. The lowest was -50.80. And the median was -3.90.

PGNX's EV/EBIT is ranked lower than
79% of the 252 Companies
in the Global Biotechnology industry.

( Industry Median: 19.98 vs. PGNX: 49.71 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt). Progenics Pharmaceuticals Inc's enterprise value for the quarter that ended in Sep. 2016 was $344.67 Mil. Progenics Pharmaceuticals Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2016 was $-39.30 Mil. Progenics Pharmaceuticals Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2016 was -11.40%.


Definition

Progenics Pharmaceuticals Inc's EV/EBIT for today is calculated as:

EV/EBIT=Enterprise Value (Today)/Earnings Before Interest and Taxes (EBIT) (TTM)
=520.451/-39.304
=-13.24

Progenics Pharmaceuticals Inc's current Enterprise Value is $520.45 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Progenics Pharmaceuticals Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2016 was $-39.30 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

This is a more accurate valuation of companies' operation because it consider the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt).

Progenics Pharmaceuticals Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2016 is calculated as:

Earnings Yield (Joel Greenblatt) (Q: Sep. 2016 )=EBIT (TTM)/Enterprise Value (Q: Sep. 2016 )
=-39.304/344.6675
=-11.40 %

Progenics Pharmaceuticals Inc's Enterprise Value for the quarter that ended in Sep. 2016 was $344.67 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Progenics Pharmaceuticals Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2016 was $-39.30 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Related Terms

Enterprise Value, Earnings Yield (Joel Greenblatt), Earnings Before Interest and Taxes (EBIT)


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Progenics Pharmaceuticals Inc Annual Data

Dec06Dec07Dec08Dec09Dec10Dec11Dec12Dec13Dec14Dec15
ev2ebit -18.71-7.91-3.90-1.53-1.9021.23-2.25-6.01120.80-9.03

Progenics Pharmaceuticals Inc Semi-Annual Data

Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16
ev2ebit -5.3836.97120.80126.81232.50-6.87-9.03-5.74-6.5832.92
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK